Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury

Andres Hurtado, Alexander Marcillo, Beata Frydel, Mary B Bunge, Helen Bramlett, W. Dalton Dietrich

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This study was initiated due to an NIH "Facilities of Research-Spinal Cord Injury" contract to support independent replication of published studies. Transient blockage of the CD11d/CD18 integrin has been reported to reduce secondary neuronal damage as well as to improve functional recovery after spinal cord injury (SCI) in rats. The purpose of this study was to determine whether treatment with an anti-CD11d monoclonal antibody (mAb) would improve motor performance, reduce pain and histopathological damage in animals following clip-compression injury as reported. Adult male Wistar rats (250. g) were anesthetized with isoflurane, and the T12 spinal cord exposed by T10 and T11 dorsal laminectomies followed by a 60. s period of clip compression utilizing a 35. g clip. Control animals received an isotype-matched irrelevant antibody (1B7) while the treated group received the anti-CD11d mAb (217. L; 1.0. mg/kg) systemically. Open-field locomotion and sensory function were assessed and animals were perfusion-fixed at twelve weeks after injury for quantitative histopathological analysis. As compared to 1B7, 217. L treated animals showed an overall non-significant trend to better motor recovery. All animals showed chronic mechanical allodynia and anti-CD11d mAb treatment did not significantly prevent its development. Histopathological analysis demonstrated severe injury to gray and white matter after compression with a non-significant trend in anti-CD11d protection compared to control animals for preserved myelin. Although positive effects with the anti-CD11d mAb treatment have been reported after compressive SCI, it is suggested that this potential treatment requires further investigation before clinical trials in spinal cord injured patients are implemented.

Original languageEnglish
Pages (from-to)606-611
Number of pages6
JournalExperimental Neurology
Volume233
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Spinal Cord Compression
Spinal Cord Injuries
Monoclonal Antibodies
Surgical Instruments
Spinal Cord
Wounds and Injuries
Therapeutics
Laminectomy
Isoflurane
Hyperalgesia
Locomotion
Myelin Sheath
Contracts
Integrins
Wistar Rats
Perfusion
Clinical Trials
Pain
Antibodies
Research

Keywords

  • Inflammation
  • Integrin
  • Locomotor
  • Rat
  • Spinal cord injury

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury. / Hurtado, Andres; Marcillo, Alexander; Frydel, Beata; Bunge, Mary B; Bramlett, Helen; Dalton Dietrich, W.

In: Experimental Neurology, Vol. 233, No. 2, 01.02.2012, p. 606-611.

Research output: Contribution to journalArticle

Hurtado, Andres ; Marcillo, Alexander ; Frydel, Beata ; Bunge, Mary B ; Bramlett, Helen ; Dalton Dietrich, W. / Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury. In: Experimental Neurology. 2012 ; Vol. 233, No. 2. pp. 606-611.
@article{45431d9a8983455b9318e6e65845faec,
title = "Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury",
abstract = "This study was initiated due to an NIH {"}Facilities of Research-Spinal Cord Injury{"} contract to support independent replication of published studies. Transient blockage of the CD11d/CD18 integrin has been reported to reduce secondary neuronal damage as well as to improve functional recovery after spinal cord injury (SCI) in rats. The purpose of this study was to determine whether treatment with an anti-CD11d monoclonal antibody (mAb) would improve motor performance, reduce pain and histopathological damage in animals following clip-compression injury as reported. Adult male Wistar rats (250. g) were anesthetized with isoflurane, and the T12 spinal cord exposed by T10 and T11 dorsal laminectomies followed by a 60. s period of clip compression utilizing a 35. g clip. Control animals received an isotype-matched irrelevant antibody (1B7) while the treated group received the anti-CD11d mAb (217. L; 1.0. mg/kg) systemically. Open-field locomotion and sensory function were assessed and animals were perfusion-fixed at twelve weeks after injury for quantitative histopathological analysis. As compared to 1B7, 217. L treated animals showed an overall non-significant trend to better motor recovery. All animals showed chronic mechanical allodynia and anti-CD11d mAb treatment did not significantly prevent its development. Histopathological analysis demonstrated severe injury to gray and white matter after compression with a non-significant trend in anti-CD11d protection compared to control animals for preserved myelin. Although positive effects with the anti-CD11d mAb treatment have been reported after compressive SCI, it is suggested that this potential treatment requires further investigation before clinical trials in spinal cord injured patients are implemented.",
keywords = "Inflammation, Integrin, Locomotor, Rat, Spinal cord injury",
author = "Andres Hurtado and Alexander Marcillo and Beata Frydel and Bunge, {Mary B} and Helen Bramlett and {Dalton Dietrich}, W.",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.expneurol.2010.11.015",
language = "English",
volume = "233",
pages = "606--611",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury

AU - Hurtado, Andres

AU - Marcillo, Alexander

AU - Frydel, Beata

AU - Bunge, Mary B

AU - Bramlett, Helen

AU - Dalton Dietrich, W.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - This study was initiated due to an NIH "Facilities of Research-Spinal Cord Injury" contract to support independent replication of published studies. Transient blockage of the CD11d/CD18 integrin has been reported to reduce secondary neuronal damage as well as to improve functional recovery after spinal cord injury (SCI) in rats. The purpose of this study was to determine whether treatment with an anti-CD11d monoclonal antibody (mAb) would improve motor performance, reduce pain and histopathological damage in animals following clip-compression injury as reported. Adult male Wistar rats (250. g) were anesthetized with isoflurane, and the T12 spinal cord exposed by T10 and T11 dorsal laminectomies followed by a 60. s period of clip compression utilizing a 35. g clip. Control animals received an isotype-matched irrelevant antibody (1B7) while the treated group received the anti-CD11d mAb (217. L; 1.0. mg/kg) systemically. Open-field locomotion and sensory function were assessed and animals were perfusion-fixed at twelve weeks after injury for quantitative histopathological analysis. As compared to 1B7, 217. L treated animals showed an overall non-significant trend to better motor recovery. All animals showed chronic mechanical allodynia and anti-CD11d mAb treatment did not significantly prevent its development. Histopathological analysis demonstrated severe injury to gray and white matter after compression with a non-significant trend in anti-CD11d protection compared to control animals for preserved myelin. Although positive effects with the anti-CD11d mAb treatment have been reported after compressive SCI, it is suggested that this potential treatment requires further investigation before clinical trials in spinal cord injured patients are implemented.

AB - This study was initiated due to an NIH "Facilities of Research-Spinal Cord Injury" contract to support independent replication of published studies. Transient blockage of the CD11d/CD18 integrin has been reported to reduce secondary neuronal damage as well as to improve functional recovery after spinal cord injury (SCI) in rats. The purpose of this study was to determine whether treatment with an anti-CD11d monoclonal antibody (mAb) would improve motor performance, reduce pain and histopathological damage in animals following clip-compression injury as reported. Adult male Wistar rats (250. g) were anesthetized with isoflurane, and the T12 spinal cord exposed by T10 and T11 dorsal laminectomies followed by a 60. s period of clip compression utilizing a 35. g clip. Control animals received an isotype-matched irrelevant antibody (1B7) while the treated group received the anti-CD11d mAb (217. L; 1.0. mg/kg) systemically. Open-field locomotion and sensory function were assessed and animals were perfusion-fixed at twelve weeks after injury for quantitative histopathological analysis. As compared to 1B7, 217. L treated animals showed an overall non-significant trend to better motor recovery. All animals showed chronic mechanical allodynia and anti-CD11d mAb treatment did not significantly prevent its development. Histopathological analysis demonstrated severe injury to gray and white matter after compression with a non-significant trend in anti-CD11d protection compared to control animals for preserved myelin. Although positive effects with the anti-CD11d mAb treatment have been reported after compressive SCI, it is suggested that this potential treatment requires further investigation before clinical trials in spinal cord injured patients are implemented.

KW - Inflammation

KW - Integrin

KW - Locomotor

KW - Rat

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84856515395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856515395&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2010.11.015

DO - 10.1016/j.expneurol.2010.11.015

M3 - Article

C2 - 21145887

AN - SCOPUS:84856515395

VL - 233

SP - 606

EP - 611

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -